Coleman, R.L., Sill, M. and Aghajanian, C. (2013) A Phase II Evaluation of the Potent, Highly Selective PARP Inhibitor Veliparib in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a Germline BRCA1 or BRCA2 Mutation—A Gynecologic Oncology Group Study. Proceedings of Society of Gynecologic Oncology 45th Annual Meeting on Women’s Cancer, Tampa, 22-25 March 2014, Abstract 136. - References

Browse Menu >>

Browse Subjects >>

Computer Science & Communications

Earth & Environmental Sciences

Social Sciences & Humanities

Why Us? >>

- Open Access
- Peer-reviewed
- Rapid publication
- Lifetime hosting
- Free indexing service
- Free promotion service
- More citations
- Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

Contact Us >>

customer@scirp.org

+86 18163351462(WhatsApp)

1655362766

Paper Publishing WeChat

Book Publishing WeChat

(or Email:book@scirp.org)

Article citations
More>>

Coleman, R.L., Sill, M. and Aghajanian, C. (2013) A Phase II Evaluation of the Potent, Highly Selective PARP Inhibitor Veliparib in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a Germline BRCA1 or BRCA2 Mutation—A Gynecologic Oncology Group Study. Proceedings of Society of Gynecologic Oncology 45th Annual Meeting on Women’s Cancer, Tampa, 22-25 March 2014, Abstract 136.

has been cited by the following article:

TITLE: Current Possible Drug Therapies for Ovarian Cancer

AUTHORS: Jungyeob Seoung, Young-Han Park, Chaechun Rhim, Sungju Kim

KEYWORDS: Ovarian Cancer, Intraperitoneal Chemotherapy, Targeting Therapy

JOURNAL NAME: Journal of Cancer Therapy, Vol.5 No.13, November 7, 2014

ABSTRACT: Ovarian cancer is the most aggressive gynecologic cancer of the heterogenous phenotypes. Development of the new chemotherapeutic agents and drug delivery mode makes better outcomes for patient treatments. Optimal cytoreductive therapy followed by molecular targeting therapy, intraperitoneal chemotherapy and dose dense chemotherapy is a hot therapeutic concept in ovarian cancers. In our review, we will introduce recent therapeutic advances in epithelial ovarian cancer patients.

Open Access

CHK21100delC, I157T, IVS2 +IG > A, BRCA1 and BRCA2 Mutation Analysis in JF305: A Pancreatic Cancer Cell Line

Charles Ndawula Jr., Xueli Yang, Xiaohai Gong, Jian Jin

DOI: 10.4236/jbm.2014.21007 3,110 Downloads 5,551 Views Citations

Pub. Date: March 21, 2014

Open Access

Oncoplastic Breast Surgery in Gynecologic Oncology Breast Pole to the National Institute of Rabat

J. A. M’bongo, Y. El Alami, W. L. Tatsipie Meukem, F. Tijami, Z. Hanchi, H. Hachi

DOI: 10.4236/ojog.2019.97097 427 Downloads 737 Views Citations

Pub. Date: July 22, 2019

Open Access

Evaluation of the BRCA1/2 mutation as a prognostic marker in primary peritoneal serous cancer

Naoto Furukawa, Sumire Ohno, Takahiko Kasai, Sachiko Morioka, Fuminori Ito, Yasuhito Tanase, Shoji Haruta, Seiji Kanayama, Ryuji Kawaguchi, Shozo Yoshida, Hiroshi Kobayashi

DOI: 10.4236/ojog.2013.39119 3,186 Downloads 4,377 Views Citations

Pub. Date: November 7, 2013

Open Access

A Pilot Study of Gemcitabine and Epirubicin Combination Chemotherapy as a Salvage Regimen for Recurrent Platinum Resistant and/or Refractory Epithelial Ovarian Cancer

Abd El Halim Abu-Hamar

DOI: 10.4236/jct.2011.24066 4,739 Downloads 7,892 Views Citations

Pub. Date: October 12, 2011

Open Access

Phase II Study of Carboplatin and Pemetrexed Followed by Gefitinib for Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive EGFR Mutation

Saki Manabe, Fumihiro Oshita, Shuji Murakami, Tetsuro Kondo, Haruhiro Saito, Takeshi Kaneko, Kouzo Yamada

DOI: 10.4236/jct.2015.615132 3,424 Downloads 4,180 Views Citations

Pub. Date: December 14, 2015